CAGE Bio Reports Strong Results from its Phase 2b Atopic Dermatitis Trial

By CAGE Bio Inc.

The investigational topical drug CGB-500 outperformed efficacy benchmarks while meeting safety endpoints

59% of patients achieved IGA treatment success

71% of patients experienced ≥4-point improvement in worst itch

SAN CARLOS, Calif. , Sept. 4, 2025 /PRNewswire/ -- CAGE Bio, a biotechnology company advancing ionic liquid–based therapies for immune-mediated skin diseases, today announced positive topline results from its double-blinded, Phase 2b dose-ranging trial of CGB-500 in patients with atopic dermatitis (AD). Globally, AD affects over 200 million people of which ~92% have <10% affected body surface area 1 , of which ~40% suffer from moderate to severe disease. In the US alone, 6.6 million people suffer from moderate to severe atopic dermatitis 2 and